ReviewFuture oncology (London, England)2013
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
Review in Future oncology (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.Journal for immunotherapy of cancer · 2023Article
- Glioblastoma, an opportunity T cell trafficking could bring for the treatment.Molecular biology reports · 2022Review
- Immune cell landscape and immunotherapy of medulloblastoma.Pediatric investigation · 2021Review
- Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?Frontiers in immunology · 2021Review
- Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.Frontiers in immunology · 2020Review
- HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma.Oncology reports · 2019Article
- Harnessing the immune system in glioblastoma.British journal of cancer · 2018Review
- Current state and future prospects of immunotherapy for glioma.Immunotherapy · 2018Review
- Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.Immunology · 2017Article
- Recent advances and future of immunotherapy for glioblastoma.Expert opinion on biological therapy · 2016Review
- Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.Journal of neuro-oncology · 2015Article
- Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.Cancer immunology research · 2015Article
- Overview of current immunotherapeutic strategies for glioma.Immunotherapy · 2015Review
- A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.Oncoimmunology · 2013Article
- Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Modest improvement in brain tumor patient survival has been achieved through advances in surgical, adjuvant radiation and chemotherapeutic strategies. However, these traditional approaches have been unsuccessful in permanently controlling these aggressive tumors, with recurrence being quite common. Hence, there is a need for novel therapeutic approaches that specifically target the molecularly diverse brain tumor cell population. The ability of the immune system to recognize altered tumor cells while avoiding surrounding normal cells offers an enormous advantage over the nonspecific nature of the conventional treatment schemes. Therefore, immunotherapy represents a promising approach that may supplement the standard therapies in eliminating the residual brain tumor cells. This review summarizes different immunotherapeutic approaches currently being tested for malignant brain tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.